Ramat Gan, Israel, March 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
(RTTNews) - Can-Fite BioPharma (CANF) announced that it received a single FDA approval for the compassionate use treatment of a U.S. based pancreatic cancer patient with its anti-cancer drug ...
Namodenoson has received FDA approval for compassionate use in a U.S. pancreatic cancer patient, despite not being fully approved yet. The drug targets the A3 adenosine receptor, showing potential in ...
The Food and Drug Administration removed an obstacle from of its "compassionate use" policy this month, eliminating some paperwork that physicians must do to obtain experimental drugs for some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback